Allogene Therapeutics (ALLO)

ALLO Cell Therapy

BiotechSign Signal Grade

F
Signal Grade
31.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
51
Clinical Activity
38
Short Interest
70

Pipeline Overview

Therapeutic Focus
Cell Therapysrc

Clinical Trial Activity

5
Clinical Trials
(ClinicalTrials.gov aggregate)
3 Phase 1, 2 Phase 2
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
20.6 months
Cash Runway Estimate
51/100
Dilution Score
40Warrant Risk
40Convertible Risk
97Offering Ability

Dilution score: 51/100 (HIGH), 20.6 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

22.10%
Float Shorted
11.3
Days to Cover
HIGH
Squeeze Risk
+0.8%
SI Change
STABLE
Trend
59,600,117
Shares Short

Short interest: 22.1% of float, squeeze risk: HIGH

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Allogene Therapeutics.

Full ALLO Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.